In the past week, RCKT stock has gone up by 35.96%, with a monthly decline of -13.88% and a quarterly plunge of -30.50%. The volatility ratio for the week is 10.32%, and the volatility levels for the last 30 days are 10.34% for Rocket Pharmaceuticals Inc The simple moving average for the last 20 days is 12.66% for RCKT stock, with a simple moving average of -50.71% for the last 200 days.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
Additionally, the 36-month beta value for RCKT is 1.03. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for RCKT is 98.94M and currently, short sellers hold a 12.57% ratio of that float. The average trading volume of RCKT on April 21, 2025 was 2.20M shares.
RCKT) stock’s latest price update
The stock of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has increased by 13.19 when compared to last closing price of 6.33. Despite this, the company has experienced a 35.96% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-10 that Rocket Pharmaceuticals’ gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants. The near-term outlook driven by clinical milestones for RP-A601, RP-A501, and potential Kresladi approval, with the current share price at $5 offering significant value. Rocket has $372M in cash, funding operations through 1H 2026, but will likely need financing post-positive data readout or Kresladi approval for commercialization.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with BMO Capital Markets repeating the rating for RCKT by listing it as a “Outperform.” The predicted price for RCKT in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on March 12, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $32. The rating they have provided for RCKT stocks is “Outperform” according to the report published on December 30th, 2024.
Jefferies gave a rating of “Buy” to RCKT, setting the target price at $29 in the report published on December 18th of the previous year.
RCKT Trading at -12.30% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.44% of loss for the given period.
Volatility was left at 10.34%, however, over the last 30 days, the volatility rate increased by 10.32%, as shares sank -12.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.42% lower at present.
During the last 5 trading sessions, RCKT rose by +40.61%, which changed the moving average for the period of 200-days by -62.54% in comparison to the 20-day moving average, which settled at $6.37. In addition, Rocket Pharmaceuticals Inc saw -43.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Shah Gaurav, who purchase 20,000 shares at the price of $5.08 back on Apr 10 ’25. After this action, Shah Gaurav now owns 792,680 shares of Rocket Pharmaceuticals Inc, valued at $101,600 using the latest closing price.
Patel Kinnari, the of Rocket Pharmaceuticals Inc, purchase 21,099 shares at $4.70 during a trade that took place back on Apr 09 ’25, which means that Patel Kinnari is holding 26,774 shares at $99,165 based on the most recent closing price.
Stock Fundamentals for RCKT
The total capital return value is set at -0.56. Equity return is now at value -54.14, with -47.30 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -8.23. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -144.86.
Currently, EBITDA for the company is -273.2 million with net debt to EBITDA at 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.30.
Conclusion
In conclusion, Rocket Pharmaceuticals Inc (RCKT) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
